Cargando…
Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
RHI-βG-PEG, formed by linking poly(ethylene glycol)-modified β-glucuronidase to Mab RH1, was employed to examine bystander killing of antigen-negative N1S1 rat hepatoma cells by activation of a glucuronide prodrug (BHAMG) of p-hydroxyaniline mustard (pHAM) at antigen-positive AS-30D rat hepatoma cel...
Autores principales: | Cheng, T L, Wei, S L, Chen, B M, Chern, J W, Wu, M F, Liu, P W, Roffler, S R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362709/ https://www.ncbi.nlm.nih.gov/pubmed/10188879 http://dx.doi.org/10.1038/sj.bjc.6690221 |
Ejemplares similares
-
Anti-tumour activity and toxicity of the new prodrug9-aminocamptothecin glucuronide (9ACG) in mice
por: Prijovich, Z M, et al.
Publicado: (2002) -
A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer
por: Houba, P H J, et al.
Publicado: (2001) -
Demonstration of anti-tumour bystander killing with prodrug-preloaded suicide gene-engineered tumour cells: a potential improvement for cancer therapeutics
por: Zweiri, Jehad, et al.
Publicado: (2020) -
A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
por: Haisma, H. J., et al.
Publicado: (1992) -
Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
por: Dachs, Gabi U., et al.
Publicado: (2009)